159 related articles for article (PubMed ID: 35715715)
1. What is this image? 2022 image 1 result: radiologic improvement of transthyretin cardiac amyloidosis after treatment with tafamidis.
Mekritthikrai R; Gomez-Valencia J; Malhotra S
J Nucl Cardiol; 2022 Aug; 29(4):1500-1502. PubMed ID: 35715715
[No Abstract] [Full Text] [Related]
2. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal evolution of ventricular function and cardiac magnetic resonance imaging tissue characteristics in tafamidis-treated transthyretin amyloid cardiomyopathy.
Dobner S; Bernhard B; Wieser M; Wahl A; Stark AW; Köchli V; Spano G; Boscolo Berto M; Johner C; Elchinova E; Tanner G; Safarkhanlo Y; Stortecky S; Schütze J; Hunziker Munsch L; Gräni C
Amyloid; 2024 Jun; 31(2):145-147. PubMed ID: 38069637
[No Abstract] [Full Text] [Related]
4. A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.
Endo J; Sano M; Izumiya Y; Tsujita K; Nakamura K; Tahara N; Kuwahara K; Inomata T; Ueda M; Sekijima Y; Ando Y; Tsutsui H; Isobe M; Fukuda K
Circ J; 2019 Dec; 84(1):15-17. PubMed ID: 31735731
[TBL] [Abstract][Full Text] [Related]
5. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
Fujita T; Inomata T; Kaida T; Iida Y; Ikeda Y; Nabeta T; Ishii S; Maekawa E; Naruke T; Koitabashi T; Kitamura E; Sekijima Y; Ako J
Cardiology; 2017; 137(2):74-77. PubMed ID: 28152524
[TBL] [Abstract][Full Text] [Related]
6. Transthyretin Stabilizer Is Associated With Expanding Apical Sparing Area and Improving Global Cardiac Function in a Patient With Wild-Type Cardiac Amyloidosis.
Kato TS; Ikeda N; Maurer MS; Ando Y; Tanno K
Circ J; 2019 Feb; 83(3):690. PubMed ID: 30185690
[No Abstract] [Full Text] [Related]
7. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
[No Abstract] [Full Text] [Related]
8. Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?
Falk RH
Eur Heart J; 2019 Mar; 40(12):1009-1012. PubMed ID: 30668704
[No Abstract] [Full Text] [Related]
9. Tafamidis Treatment Decreases
Yu AL; Chen YC; Tsai CH; Chao CC; Su MY; Juang JJ; Lee MJ; Hsieh ST; Cheng MF; Lin YH
JACC Cardiovasc Imaging; 2023 Jun; 16(6):866-867. PubMed ID: 36881423
[No Abstract] [Full Text] [Related]
10. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
[TBL] [Abstract][Full Text] [Related]
11. Serial
Okada A; Tateishi E; Morita Y; Ohta-Ogo K; Izumi C
Circ Heart Fail; 2023 Jan; 16(1):e009595. PubMed ID: 36541213
[No Abstract] [Full Text] [Related]
12. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
Maurer MS; Schwartz JH; Gundapaneni B; Elliott PM; Merlini G; Waddington-Cruz M; Kristen AV; Grogan M; Witteles R; Damy T; Drachman BM; Shah SJ; Hanna M; Judge DP; Barsdorf AI; Huber P; Patterson TA; Riley S; Schumacher J; Stewart M; Sultan MB; Rapezzi C;
N Engl J Med; 2018 Sep; 379(11):1007-1016. PubMed ID: 30145929
[TBL] [Abstract][Full Text] [Related]
13. Letter by Baldovino et al Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy".
Baldovino S; Costanzo P; Roccatello D
Circ Heart Fail; 2022 Jul; 15(7):e009617. PubMed ID: 35748294
[No Abstract] [Full Text] [Related]
14. Response by Elliott et al to Letter Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy".
Elliott P; Gundapaneni B; Sultan MB
Circ Heart Fail; 2022 Jul; 15(7):e009637. PubMed ID: 35748240
[No Abstract] [Full Text] [Related]
15. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
[TBL] [Abstract][Full Text] [Related]
16. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
Shintani Y; Okada A; Morita Y; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Ohta-Ogo K; Kanzaki H; Ishibashi-Ueda H; Yasuda S; Shimazaki C; Yoshinaga T; Yazaki M; Sekijima Y; Izumi C
ESC Heart Fail; 2019 Feb; 6(1):232-236. PubMed ID: 30478886
[TBL] [Abstract][Full Text] [Related]
17. [Diagnosis and treatment of cardiac transthyretin amyloidosis. Innovative therapy with tafamidis.].
Legrand D; Nyssen A; Jackers L; Brogneaux C; Pirotte I; Grayet D; Lacremans D; Magnée M
Rev Med Liege; 2022 Jan; 77(1):63-68. PubMed ID: 35029343
[TBL] [Abstract][Full Text] [Related]
18. Specific Therapy in Transthyretin Amyloid Cardiomyopathy: Future Perspectives Beyond Tafamidis.
Saro R; Allegro V; Merlo M; Dore F; Sinagra G; Porcari A
Heart Fail Clin; 2024 Jul; 20(3):343-352. PubMed ID: 38844305
[TBL] [Abstract][Full Text] [Related]
19. [Experience with tafamidis in a patient with transthyretin amyloidosis].
Nasonova SN; Zhirov IV; Magomedov MM; Saidova MA; Osmolovskaya YF; Tereschenko SN
Kardiologiia; 2020 Jan; 60(3):155-160. PubMed ID: 32375630
[TBL] [Abstract][Full Text] [Related]
20. Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy.
Rettl R; Wollenweber T; Duca F; Binder C; Cherouny B; Dachs TM; Camuz Ligios L; Schrutka L; Dalos D; Beitzke D; Loewe C; Badr Eslam R; Kastner J; Hacker M; Bonderman D
Eur Heart J Cardiovasc Imaging; 2023 Jul; 24(8):1019-1030. PubMed ID: 36881774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
